GLP-1 Daily: Ozempic & Wegovy News
Novo and GoodRx Offer Employers a Side Door to GLP-1 Coverage; Korea's Obesity-Drug Demand and Smuggling Surge; Sun Pharma Wins India Nod for a Generic Semaglutide Pill
Monday, November 2, 2026 · 8 min
As employers drop weight-loss GLP-1 coverage for 2027, Novo Nordisk's deal with Andel and GoodRx's new Employer Direct let companies chip in on cash prices outside insurance. Plus: South Korea's prescriptions and intercepted illegal imports surge, and Sun Pharma gets Indian approval for a generic semaglutide diabetes pill.
Listen
Show notes
As employers drop weight-loss GLP-1 coverage for 2027, Novo Nordisk's deal with Andel and GoodRx's new Employer Direct let companies chip in on cash prices outside insurance. Plus: South Korea's prescriptions and intercepted illegal imports surge, and Sun Pharma gets Indian approval for a generic semaglutide diabetes pill.
In this episode
- As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround — Ajmc
“The deal covers both injectable semaglutide, including the higher-dose semaglutide HD, and the once-daily semaglutide pill. Each employer chooses how much to contribute toward treatment, which lowers what employees pay out of pocket while the employer keeps control over its…”
- Koreans aren't rushing to embrace homegrown weight-loss drug — yet | Aju Press — Aju Press
“Lawmakers say price differences have encouraged purchases abroad. The Korea Customs Service intercepted illegally imported obesity drugs 5,030 times in the first eight months of this year, 4.2 times the total for 2025.”
- Sun Pharma Secures Approval for Generic Semaglutide Pill in India, ETPharma — Abhijeet Singh
“Indian Pharma major, Sun Pharmaceutical Industries has secured regulatory nod to manufacturer and market its generic semaglutide pill in India. The once-daily drug, therapeutically equivalent to Novo’s Rybelsus, is approved for the treatment for type-2 diabetes and covers three…”